These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Standardizing assessment of adverse effects in rheumatology clinical trials. Status of OMERACT Toxicity Working Group March 2000: towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapies. Woodworth TG; Furst DE; Strand V; Kempeni J; Fenner H; Lau CS; Miller F; Day R; Lipani J; Brooks P J Rheumatol; 2001 May; 28(5):1163-9. PubMed ID: 11361207 [TBL] [Abstract][Full Text] [Related]
4. Patient based method of assessing adverse events in clinical trials in rheumatology: the revised Stanford Toxicity Index. Welch V; Singh G; Strand V; Fries J; Boers M; Ramey D; Day RO; Brooks P; Tugwell P; Clinch J; Kristjansson B J Rheumatol; 2001 May; 28(5):1188-91. PubMed ID: 11361211 [TBL] [Abstract][Full Text] [Related]
5. Area under the curve for the American College of Rheumatology improvement criteria: a valid addition to existing criteria in rheumatoid arthritis? van Riel PL; van Gestel AM Arthritis Rheum; 2001 Jul; 44(7):1719-21. PubMed ID: 11465727 [No Abstract] [Full Text] [Related]
6. Challenges in analgesic drug development. Hewitt DJ; Hargreaves RJ; Curtis SP; Michelson D Clin Pharmacol Ther; 2009 Oct; 86(4):447-50. PubMed ID: 19675542 [No Abstract] [Full Text] [Related]
7. Issues in the design of new clinical trials for rheumatoid arthritis therapeutics. Schwieterman WD Nat Clin Pract Rheumatol; 2008 Dec; 4(12):641-8. PubMed ID: 19037225 [TBL] [Abstract][Full Text] [Related]
9. Statistics and the relationship of clinical research to clinical practice. Khuder SA; Kahaleh B J Rheumatol; 2009 Feb; 36(2):219-20. PubMed ID: 19208555 [No Abstract] [Full Text] [Related]
10. [Roaming through methodology. XII. Pragmatic and pathophysiologic trials: a question of goal formulation]. Algra A; van der Graaf Y Ned Tijdschr Geneeskd; 1999 Mar; 143(10):514-7. PubMed ID: 10321260 [TBL] [Abstract][Full Text] [Related]
11. Dose selection and comparator drugs in schizophrenia research. Kane JM J Clin Psychiatry; 2001; 62 Suppl 9():29-32; discussion 33-4. PubMed ID: 11379828 [TBL] [Abstract][Full Text] [Related]
12. A primer on the design, conduct, and interpretation of clinical trials. Appel LJ Clin J Am Soc Nephrol; 2006 Nov; 1(6):1360-7. PubMed ID: 17699370 [TBL] [Abstract][Full Text] [Related]
13. [The limits of controlled clinical studies: the case of rheumatology]. Portioli I Ann Ital Med Int; 2000; 15(1):39-46. PubMed ID: 10842890 [TBL] [Abstract][Full Text] [Related]
14. Bias in uncontrolled therapeutic trials in rheumatology due to selection of populations with extreme characteristics. Ioannidis JP; Karassa FB J Rheumatol; 2001 Aug; 28(8):1881-7. PubMed ID: 11508595 [TBL] [Abstract][Full Text] [Related]
15. Initial human trials with an investigational new drug (phase I and 2): planning an management. Vaidya AB; Vaidya RA J Postgrad Med; 1981 Oct; 27(4):197-213. PubMed ID: 7338825 [No Abstract] [Full Text] [Related]
16. A proposed revision to the ACR20: the hybrid measure of American College of Rheumatology response. American College of Rheumatology Committee to Reevaluate Improvement Criteria Arthritis Rheum; 2007 Mar; 57(2):193-202. PubMed ID: 17330293 [TBL] [Abstract][Full Text] [Related]
17. The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria Arthritis Rheum; 2004 Nov; 50(11):3418-26. PubMed ID: 15529383 [TBL] [Abstract][Full Text] [Related]
18. Ongoing patient randomization: an innovation in medical care research. Cargill V; Cohen D; Kroenke K; Neuhauser D Health Serv Res; 1986 Dec; 21(5):663-78. PubMed ID: 3546202 [TBL] [Abstract][Full Text] [Related]
19. Quantitative rheumatology: a survey of outcome measurement procedures in routine rheumatology outpatient practice in Canada. Bellamy N; Kaloni S; Pope J; Coulter K; Campbell J J Rheumatol; 1998 May; 25(5):852-8. PubMed ID: 9598879 [TBL] [Abstract][Full Text] [Related]
20. An open study of botulinum-A toxin treatment of trigeminal neuralgia. Zakrzewska JM; Cohen J; Brown J; Alksne J; Gemillion H; Linskey M; Sirois D; Pollock B Neurology; 2006 May; 66(9):1458-9; author reply 1458-9. PubMed ID: 16685762 [No Abstract] [Full Text] [Related] [Next] [New Search]